Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gain Therapeutics (GANX)
NASDAQ:GANX
Gain Therapeutics (GANX) Stock Price & Analysis
116 Followers
GANX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.80 - $6.19
Previous Close$3.34
Volume32.12K
Average Volume (3M)32.27K
Market Cap
$42.42M
Enterprise ValueN/A
Total Cash (Recent Filing)$16.19M
Total Debt (Recent Filing)$1.14M
Price to Earnings (P/E)-1.8
Beta0.99
Next Earnings
Nov 10, 2023EPS Estimate
-$0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.83
Shares Outstanding12,699,422
10 Day Avg. Volume34,963
30 Day Avg. Volume32,271
Standard Deviation0.13
R-Squared0.02
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)3.97
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$10.00Price Target Upside199.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Gain Therapeutics News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GANX FAQ
What was Gain Therapeutics’s price range in the past 12 months?
Gain Therapeutics lowest stock price was $2.80 and its highest was $6.19 in the past 12 months.
What is Gain Therapeutics’s market cap?
Currently, no data Available
When is Gain Therapeutics’s upcoming earnings report date?
Gain Therapeutics’s upcoming earnings report date is Nov 10, 2023 which is in 47 days.
How were Gain Therapeutics’s earnings last quarter?
Gain Therapeutics released its earnings results on Aug 10, 2023. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.308 by -$0.312.
Is Gain Therapeutics overvalued?
According to Wall Street analysts Gain Therapeutics’s price is currently Undervalued.
Does Gain Therapeutics pay dividends?
Gain Therapeutics does not currently pay dividends.
What is Gain Therapeutics’s EPS estimate?
Gain Therapeutics’s EPS estimate is -$0.45.
How many shares outstanding does Gain Therapeutics have?
Gain Therapeutics has 12,699,422 shares outstanding.
What happened to Gain Therapeutics’s price movement after its last earnings report?
Gain Therapeutics reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.308. Following the earnings report the stock price went down -5.333%.
Which hedge fund is a major shareholder of Gain Therapeutics?
Among the largest hedge funds holding Gain Therapeutics’s share is Greenlight Capital Inc. It holds Gain Therapeutics’s shares valued at 2M.
---
Gain Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (199.40% Upside)
$10.00 (199.40% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.14%
12-Months-Change
Fundamentals
Return on Equity
-115.76%
Trailing 12-Months
Asset Growth
-42.74%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Gain Therapeutics
Gain Therapeutics Inc is a development-stage biotechnology company developing novel therapeutics to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders (LSDs), including rare genetic diseases and neurological disorders. Its pipeline includes the GLB1 gene, GBA1 gene, IDUA gene, and GALC gene.
---
Top 5 ETFs holding GANX
Currently, no data available
Please return soon. This page is being updated.
Up to five ETFs with an Outperform Smart Score that hold GANX. The ETFs are listed according to market value of GANX within the ETF
Arvinas Holding Company
―
Bioxcel Therapeutics
―
Cidara Therapeutics
―
Fate Therapeutics
―
---